ERBB2 and neoplasm: The consensus was less clear to give anti-Her2 therapy to patients having negative ER and positive HER2 disease; votes were 41% for tumor size 5 mm, 32% for 6 mm, and 27% for tumors less than 5 mm to consider anti-HER2 therapy.